Is There a Role for Bevacizumab in the Treatment of Glioblastoma?

Bevacizumab gained accelerated approval from the U.S. Food and Drug Administration for use as monotherapy in progressive glioblastoma, based on improved radiologic response rates observed with bevacizumab monotherapy in two single‐arm or noncomparative phase II trials. Drs. Chi and Chamberlain discuss whether the available evidence supports the use of bevacizumab in glioblastomas.